Imiquimod (IMQ) is a toll-like receptor (TLR)7/8 agonist that has the ability to induce psoriasiform skin in humans and mice and to trigger a series of cytokines involved in the development of psoriasis, such as IL-23, IL-17, and IL-22 [2,16,17]. Here, IL22 is linked to psoriasis.